Clinical trial of atezolizumab plus chemotherapy compared with chemotherapy alone for patients with recurrent triple-negative breast cancer (IMpassion132)

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)

Cancer
Breast Cancer
Triple Negative Breast Neoplasms
Triple Negative Breast Cancer

Results
Download

Study results

LPS MO39193 IMpassion132 Interim Results October 2024 English (PDF, 0.4 MB)

LPS MO39193 IMpassion132 Final Results July 2025 Argentina Spanish (PDF, 1.0 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

Clinical trial of atezolizumab plus chemotherapy compared with chemotherapy alone for patients with recurrent triple-negative breast cancer (IMpassion132)

Study results

LPS MO39193 IMpassion132 Interim Results October 2024 English (PDF, 0.4 MB)

LPS MO39193 IMpassion132 Final Results July 2025 Argentina Spanish (PDF, 1.0 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

Clinical trial of atezolizumab plus chemotherapy compared with chemotherapy alone for patients with recurrent triple-negative breast cancer (IMpassion132)

For the latest version of this information please go to www.forpatients.roche.com